Objective

Gaining meaningful mechanistic data is becoming increasingly valuable in the discovery and development of new immunotherapies, either for immuno-oncology or for inflammatory diseases. In particular, there is strong emphasis on advanced human cellular assays that seek to mimic the complex interactions involved in the evolution of an immune response. In the setting of immuno-oncology, the inclusion of tumour cells as targets for immune attack brings greater complexity. These kinds of assays can deliver powerful insight for target validation and mechanism-of-action, but have traditionally been rather small-scale, often because of limiting cell numbers. Aquila BioMedical is a globally recognized CRO partner offering innovative science-rich solutions for drug discovery and development programs in immunology and immune-oncology. We shall discuss some of the challenges and opportunities that lie in the miniaturization of advanced cellular assays, for use in HTS